Core Insights - Lisata Therapeutics reported positive data from multiple clinical studies involving certepetide, highlighting its potential effectiveness in treating advanced solid tumors [3][4][6] - The company has formed a strategic alliance with GATC Health to utilize their AI-driven drug discovery platform, enhancing the development of certepetide and its applications [3][15] - Lisata has extended its cash runway into the first quarter of 2027, with no debt, indicating a stable financial position for ongoing operations [3][12] Business Developments - A global license agreement was established with Catalent for the use of certepetide in their SMARTag® Antibody-Drug Conjugate Technology Platform, which may enhance the targeting and effectiveness of ADCs [3][15] - The company achieved complete enrollment in the BOLSTER trial for cholangiocarcinoma ahead of schedule, with topline data expected in the fourth quarter of 2025 [8] - Certepetide has received multiple designations, including Fast Track and Orphan Drug Designation for various cancers, indicating its potential significance in oncology [5] Clinical Trial Highlights - The ASCEND trial showed promising preliminary results, with a positive trend in overall survival for patients treated with certepetide in combination with standard chemotherapy [4][6] - The CENDIFOX trial demonstrated a 50% R0 resection rate and a 70% pathologic partial response in patients with pancreatic cancer, suggesting that certepetide may enhance the effectiveness of existing therapies [8][10] - The iLSTA trial provided compelling data supporting certepetide's ability to improve immunotherapy outcomes in patients with locally advanced non-resectable pancreatic cancer [8][10] Financial Performance - For Q3 2025, operating expenses decreased to $4.4 million from $5.3 million in Q3 2024, reflecting a 17.3% reduction [9][11] - Research and development expenses were approximately $2.0 million, down 22.9% from the previous year, primarily due to lower spending in certain areas [10] - The company reported a net loss of $4.2 million for Q3 2025, compared to $4.9 million in Q3 2024, indicating improved financial management [11][19]

Core Insights - SoundHound AI, Inc. reported a strong financial performance for Q3 2025, with revenue reaching $42.0 million, a 68% increase year-over-year [6][14] - The company is expanding its presence in key vertical markets and forming strategic partnerships to enhance its AI leadership through the Agentic+ framework [1][4] Financial Highlights - Revenue for Q3 2025 was $42.0 million, up from $25.1 million in Q3 2024, marking a 68% increase [6][14] - GAAP gross margin was 42.6%, while non-GAAP gross margin was 59.3% [6][14] - GAAP net loss was $109.3 million, compared to a loss of $21.8 million in the same quarter last year [6][14] - Adjusted EBITDA loss was $14.5 million, showing an improvement from a loss of $15.9 million in Q3 2024 [6][14] Business Developments - The company launched the Amelia 7.3 update, enhancing its voice AI capabilities with Speech-to-Meaning technology [7] - Significant contracts were secured across various sectors, including automotive, healthcare, and financial services, indicating a diverse customer base [12][19] - SoundHound is raising its full-year 2025 revenue outlook to a range of $165 - $180 million [18] Strategic Partnerships and Market Position - SoundHound is working with major brands in automotive and healthcare to deploy its AI solutions, including a custom assistant for a sports car brand and a pioneering AI solution for a precision medicine provider [12][19] - The company has established partnerships with leading technology distributors and service providers to enhance its market reach [12][19] Cash Flow and Liquidity - As of September 30, 2025, the company had total cash and cash equivalents of $269 million, with no debt [16]

New leadership appointments strengthen Sight Sciences’ commitment to advancing our interventional dry eye initiatives and driving scalable operations and growthMENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating ...

-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next-generation PI3Kα pan-mut ...

Declares Quarterly Dividend of $0.68 per ShareLOUISVILLE, Ky., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Texas Roadhouse, Inc. (NasdaqGS: TXRH), today announced financial results for the 13 and 39 weeks ended September 30, 2025. Financial Results Financial results for the 13 and 39 weeks ended September 30, 2025 and September 24, 2024 were as follows: 13 Weeks Ended 39 Weeks Ended($000's, except per share amounts)September 30, 2025 September 24, 2024 % change September 30, 2025 September 24, 2024 % changeTotal rev ...

The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notification Letter Vancouver, Canada, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announ ...

Revenue Growth, Operational Discipline, and Strategic Focus Position Blink for Solid Q4 Bowie, MD., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Blink Charging Co. (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global owner, operator, and provider of electric vehicle (EV) charging equipment and services, today announced financial results for the third quarter ended September 30, 2025.THIRD QUARTER HIGHLIGHTS Third quarter service revenues grew 35.5% year-over-year (YOY) to $11.9M, driven by increased charger u ...

— Achieves Record Quarterly Revenue and EPS Despite Challenging Environment — EL MONTE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced financial results for the third quarter and nine months ended September 30, 2025. Third Quarter 2025 Financial Highlights Total revenues of $332.6 million, increased 9.7% year-over-year.Gross profit of $77.0 ...

Datavault AI ™ expands its VerifyU credentialing platform and ADIO engagement technology in entertainment copyright and nightlife, a rapidly evolving market for authentic digital verification and real-time data monetizationPHILADELPHIA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Datavault AI Inc. (Nasdaq: DVLT), a leader in data monetization, credentialing and digital engagement technologies, today announced a landmark partnership with Rodney’s Comedy Club, integrating its VerifyU, Joke Token, and ADIO® so ...

6 November 2025 Air Astana Expands Boeing 787-9 Order for Long-Haul Fleet Development Almaty, Kazakhstan – Air Astana JSC (the "Company" and, together with its subsidiary FlyArystan, the "Group"), the leading airline group in Central Asia and the Caucasus regions by revenue and fleet size, is setting course on a major long-haul fleet expansion with a new order for up to 15 Boeing 787-9 Dreamliners. This is the largest order ever placed by the Group, comprising five firm positions, five options and five purc ...